Accuray Incorporated has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its iDMS Data Management System, enabling its use with the company's TomoTherapy platform. It's designed to integrate with a wide range of technologies, including the Radixact, TomoTherapy and CyberKnife Systems, Accuray Precision Treatment Planning System, and third-party treatment planning and oncology information systems.
The iDMS System is a centralized database that shares and makes data accessible between multiple Accuray treatment delivery systems, adding flexibility and improving efficiency in the radiation therapy department. It provides an integrated platform for storing and managing all patient and treatment plan data, allowing clinicians to securely and seamlessly access the data they need to drive efficient, informed, effective radiation treatments.
"This most recent clearance reinforces Accuray's commitment to providing clinicians with options for seamless, fully integrated treatment planning and data management, enhancing department workflow efficiency," said Lionel Hadjadjeba, senior vice president, and chief commercial officer at Accuray. "The common database will make it possible for clinicians to use any available Accuray treatment system, expanding patient access to the precision and treatment versatility of our advanced radiation therapy systems."Back To Top
Accuray receives 510(k) clearance for iDMS data management TomoTherapy upgrade . Appl Rad Oncol.